{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:46:14Z","timestamp":1791294374444,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 AG046275"],"award-info":[{"award-number":["R01 AG046275"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008908","name":"Foundation for Neurologic Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008908","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Harvard NeuroDiscovery Center's NeuroBehavior Laboratory"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.nbd.2015.07.008","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T13:49:28Z","timestamp":1437918568000},"page":"372-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Anti-A\u03b2 antibodies incapable of reducing cerebral A\u03b2 oligomers fail to attenuate spatial reference memory deficits in J20 mice"],"prefix":"10.1016","volume":"82","author":[{"given":"Alexandra J.","family":"Mably","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Mc Donald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Cosme","family":"Dodart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Bard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Lemere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"O'Nuallain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2015.07.008_bb0005","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","article-title":"An effector-reduced anti-beta-amyloid (Abeta) antibody with unique Abeta binding properties promotes neuroprotection and glial engulfment of Abeta","volume":"32","author":"Adolfsson","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1172\/JCI27120","article-title":"Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Abeta antibody","volume":"116","author":"Bales","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2015.07.008_bb0015","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2015.07.008_bb0020","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1074\/jbc.M109.045187","article-title":"Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease","volume":"285","author":"Basi","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0030","author":"Biogen-Idec"},{"key":"10.1016\/j.nbd.2015.07.008_bb0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2015.07.008_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2015.07.008_bb0045","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1523\/JNEUROSCI.5171-13.2014","article-title":"Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzheimer\u2019s disease","volume":"34","author":"Born","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurobiolaging.2005.12.003","article-title":"Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage","volume":"28","author":"Burbach","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2015.07.008_bb0055","series-title":"11th International Conference on Alzheimer's and Parkinson's Diseases","article-title":"BIIB037: a fully-human monoclonal antibody that binds specifically to fibrillar abeta, and reduces amyloid burden without affecting vascular amyloid","author":"Bussiere","year":"2013"},{"key":"10.1016\/j.nbd.2015.07.008_bb0060","series-title":"11th International Conference on Alzheimer's and Parkinson's Diseases","article-title":"Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates","author":"Bussiere","year":"2013"},{"key":"10.1016\/j.nbd.2015.07.008_bb0065","author":"Chen"},{"key":"10.1016\/j.nbd.2015.07.008_bb0070","doi-asserted-by":"crossref","first-page":"23818","DOI":"10.1074\/jbc.M701078200","article-title":"Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models","volume":"282","author":"Cheng","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0075","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1523\/JNEUROSCI.2980-05.2005","article-title":"Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease","volume":"25","author":"Chin","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0080","author":"clinicaltrials.gov"},{"key":"10.1016\/j.nbd.2015.07.008_bb0085","author":"clinicaltrials.gov"},{"key":"10.1016\/j.nbd.2015.07.008_bb0090","author":"clinicaltrials.gov"},{"key":"10.1016\/j.nbd.2015.07.008_bb0095","author":"clinicaltrials.gov"},{"key":"10.1016\/j.nbd.2015.07.008_bb0105","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2015.07.008_bb0110","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"issue":"S2","key":"10.1016\/j.nbd.2015.07.008_bb0115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0197-4580(04)81916-X","article-title":"In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and selective exacerbation of CAA-associated microhemorrhage","volume":"25","author":"DeMattos","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2015.07.008_bb0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.nlm.2008.05.008","article-title":"Excitotoxic lesions restricted to the dorsal CA1 field of the hippocampus impair spatial memory and extinction learning in C57BL\/6 mice","volume":"90","author":"Dillon","year":"2008","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0125","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2015.07.008_bb0135","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1093\/brain\/awu280","article-title":"Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model","volume":"137","author":"Dorostkar","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2015.07.008_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2015.07.008_bb0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2015.07.008_bb0150","doi-asserted-by":"crossref","first-page":"26571","DOI":"10.1016\/S0021-9258(19)74350-6","article-title":"Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11","volume":"268","author":"Hilbich","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0926-6410(96)00004-3","article-title":"Maze procedures: the radial-arm and water maze compared","volume":"3","author":"Hodges","year":"1996","journal-title":"Brain Res. Cogn. Brain Res."},{"key":"10.1016\/j.nbd.2015.07.008_bb0160","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1073\/pnas.96.6.3228","article-title":"Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models","volume":"96","author":"Hsia","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2015.07.008_bb0165","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1073\/pnas.94.4.1550","article-title":"Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease","volume":"94","author":"Johnson-Wood","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2015.07.008_bb0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bbr.2011.12.021","article-title":"Cognitive phenotyping of amyloid precursor protein transgenic J20 mice","volume":"228","author":"Karl","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2015.07.008_bb0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11481-008-9114-6","article-title":"Deglycosylated anti-Abeta antibody dose\u2013response effects on pathology and memory in APP transgenic mice","volume":"3","author":"Karlnoski","year":"2008","journal-title":"J Neuroimmune Pharmacol."},{"key":"10.1016\/j.nbd.2015.07.008_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-1326-8-15","article-title":"Normal cognition in transgenic BRI2-Abeta mice","volume":"8","author":"Kim","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2015.07.008_bb0185","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1523\/JNEUROSCI.4165-12.2013","article-title":"Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease","volume":"33","author":"Kim","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0190","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1601-183X.2009.00545.x","article-title":"Isoform-specific effects of apolipoprotein E on cognitive performance in targeted-replacement mice overexpressing human APP","volume":"9","author":"Kornecook","year":"2010","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.nbd.2015.07.008_bb0195","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","article-title":"Reversible memory loss in a mouse transgenic model of Alzheimer's disease","volume":"22","author":"Kotilinek","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0200","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1515\/revneuro-2012-0041","article-title":"Neurologic and motor dysfunctions in APP transgenic mice","volume":"23","author":"Lalonde","year":"2012","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/alzrt246","article-title":"Perspectives on future Alzheimer therapies: amyloid-beta protofibrils \u2014 a new target for immunotherapy with BAN2401 in Alzheimer's disease","volume":"6","author":"Lannfelt","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2015.07.008_bb0210","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1074\/jbc.M511018200","article-title":"Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice","volume":"281","author":"Lee","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI25410","article-title":"Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model","volume":"116","author":"Levites","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2015.07.008_bb0220","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease","volume":"36","author":"Lord","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2015.07.008_bb0225","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.neurobiolaging.2014.11.022","article-title":"Tau immunization: a cautionary tale?","volume":"36","author":"Mably","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2015.07.008_bb0230","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1523\/JNEUROSCI.0381-06.2006","article-title":"Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response","volume":"26","author":"Maier","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0235","doi-asserted-by":"crossref","first-page":"36415","DOI":"10.1074\/jbc.M205208200","article-title":"Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments","volume":"277","author":"Mathews","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2015.01.005","article-title":"The aqueous phase of Alzheimer's disease brain contains assemblies built from approximately 4 and approximately 7kDa Abeta species","author":"Mc Donald","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2015.07.008_bb0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.brainres.2012.02.041","article-title":"The levels of water-soluble and triton-soluble Abeta are increased in Alzheimer's disease brain","volume":"1450","author":"McDonald","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2015.07.008_bb0250","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00227819","article-title":"Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes","volume":"84","author":"Mercken","year":"1992","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2015.07.008_bb0255","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2015.07.008_bb0260","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","article-title":"High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation","volume":"20","author":"Mucke","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0280","doi-asserted-by":"crossref","first-page":"39413","DOI":"10.1074\/jbc.M608485200","article-title":"Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles","volume":"281","author":"Oddo","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0270","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1523\/JNEUROSCI.3537-10.2010","article-title":"Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils","volume":"30","author":"O'Nuallain","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1471-4159.2011.07389.x","article-title":"A monoclonal antibody against synthetic Abeta dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Abeta","volume":"119","author":"O'Nuallain","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0265","doi-asserted-by":"crossref","first-page":"P881","DOI":"10.1016\/j.jalz.2014.07.035","article-title":"Are anti-Abeta aggregate-preferring antibodies the future for AD immunotherapy?","volume":"10","author":"O'Nuallain","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2015.07.008_bb0290","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.1073\/pnas.1133381100","article-title":"Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits","volume":"100","author":"Palop","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2015.07.008_bb0285","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2015.07.008_bb0295","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.nbd.2015.07.008_bb0300","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","article-title":"Cerebral hemorrhage after passive anti-Abeta immunotherapy","volume":"298","author":"Pfeifer","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nbd.2015.07.008_bb0305","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1523\/JNEUROSCI.4337-04.2005","article-title":"Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta","volume":"25","author":"Racke","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0310","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jnc.12305","article-title":"Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice","volume":"126","author":"Rasool","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2015.07.008_bb0315","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/hyb.1995.14.235","article-title":"Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates","volume":"14","author":"Reeves","year":"1995","journal-title":"Hybridoma"},{"key":"10.1016\/j.nbd.2015.07.008_bb0325","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.nbd.2015.07.008_bb0320","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","article-title":"Amyloid-beta\/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease","volume":"31","author":"Roberson","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0330","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1750-1326-7-28","article-title":"Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult","volume":"7","author":"Rodgers","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2015.07.008_bb0340","author":"Salloway"},{"key":"10.1016\/j.nbd.2015.07.008_bb0335","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2015.07.008_bb0345","doi-asserted-by":"crossref","first-page":"E2895","DOI":"10.1073\/pnas.1121081109","article-title":"Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model","volume":"109","author":"Sanchez","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2015.07.008_bb0350","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nrn938","article-title":"Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning","volume":"3","author":"Schenk","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2015.07.008_bb0360","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","article-title":"Immunotherapy reduces vascular amyloid-beta in PDAPP mice","volume":"28","author":"Schroeter","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0365","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.neurobiolaging.2006.04.007","article-title":"Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice","volume":"28","author":"Seabrook","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2015.07.008_bb0370","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ana.24001","article-title":"The therapeutics of Alzheimer's disease: where we stand and where we are heading","volume":"74","author":"Selkoe","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2015.07.008_bb0375","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/359325a0","article-title":"Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids","volume":"359","author":"Seubert","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2015.07.008_bb0380","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-60761-744-0_3","article-title":"Isolation of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain","volume":"670","author":"Shankar","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2015.07.008_bb0385","author":"Sperling"},{"key":"10.1016\/j.nbd.2015.07.008_bb0390","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1208\/s12248-009-9157-5","article-title":"Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease","volume":"12","author":"Tabrizi","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.nbd.2015.07.008_bb0395","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2015.07.008_bb0400","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/B978-0-12-385883-2.00012-6","article-title":"Alzheimer's disease and the amyloid beta-protein","volume":"107","author":"Walsh","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0405","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0092-8674(89)90177-3","article-title":"Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein","volume":"57","author":"Weidemann","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2015.07.008_bb0410","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W","article-title":"Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease","volume":"48","author":"Weiner","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2015.07.008_bb0415","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0805as26","article-title":"Assessment of spatial memory using the radial arm maze and Morris water maze","volume":"26","author":"Wenk","year":"2004","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0425","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","article-title":"Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition","volume":"24","author":"Wilcock","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0430","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1742-2094-1-24","article-title":"Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage","volume":"1","author":"Wilcock","year":"2004","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2015.07.008_bb0420","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1523\/JNEUROSCI.0695-06.2006","article-title":"Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice","volume":"26","author":"Wilcock","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0435","doi-asserted-by":"crossref","first-page":"e59586","DOI":"10.1371\/journal.pone.0059586","article-title":"Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease","volume":"8","author":"Wright","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2015.07.008_bb0440","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1523\/JNEUROSCI.2021-09.2009","article-title":"Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta","volume":"29","author":"Yamada","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0445","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jalz.2012.11.005","article-title":"New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF","volume":"9","author":"Yang","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.nbd.2015.07.008_bb0450","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-015-0100-y","article-title":"A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid","volume":"7","author":"Yang","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2015.07.008_bb0455","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1523\/JNEUROSCI.1676-11.2012","article-title":"Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific","volume":"32","author":"Zago","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2015.07.008_bb0460","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3233\/JAD-2010-091195","article-title":"Administration of amyloid-beta42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice","volume":"23","author":"Zhang","year":"2011","journal-title":"J. Alzheimers Dis."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996115300127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996115300127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T02:20:34Z","timestamp":1652926834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996115300127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":91,"alternative-id":["S0969996115300127"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2015.07.008","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-A\u03b2 antibodies incapable of reducing cerebral A\u03b2 oligomers fail to attenuate spatial reference memory deficits in J20 mice","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2015.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}